nj-department-of-human-services-agenda-2025-04-23_0b7.pdf
Ozempic approved to reduce kidney, cardiovascular risk
Trusted by teams at
Description
Novo Nordisk's Ozempic™ Receives FDA Approval as Sole GLP-1 Receptor Agonist for Lowering Kidney Disease and Cardiovascular Death Risk in Adults with Type 2 Diabetes and Chronic Kidney Disease.
Contract Details
Contract Amount
NA
Vendor
NOVO NORDISK
Agency
NJ Department of Human Services, NJ
Contract Type
Medication
Document Date
April 23, 2025
Contract Term
NA
More from NOVO NORDISK
Related Contracts
Town of Clayton Council Meeting Minutes August 2025
AMENDEDresolution_to_acquire_easements_for_east_main_stre.pdf
approvedLebanon Airport-Tech Park TIF Advisory Board Minutes July 2024
ONGOINGTown of Clayton Council Work Session Minutes July 2024
PENDINGTown of Clayton Council Meeting Minutes June 2024
APPROVEDMore from NJ Department of Human Services
New Jersey Drug Utilization Review Board Agenda April 2026
nj-department-of-human-services-drug-utilization-review-board-agenda-october-2025_148.pdf
nj-dhs-durb-agenda-drug-protocol-updates-utilization-trends-jul-16-2025_a3a.pdf
nj-dept-of-human-services-durb-agenda-drug-utilization-protocol-reviews-july-16-2025_b3a.pdf
nj-department-of-human-services-agenda-2025-04-23_0b7.pdf
Want to learn more?
Get alerts on contract renewals, new awards, and vendor activity.
Bring us your territory.
We'll show you what is forming.
See live SLED buying signals, source docs, decision-makers, contract context, and the next step into your CRM or pipeline.